Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

Abstract Quadruplet induction, autologous hematopoietic cell transplant (AHCT), and measurable residual disease (MRD) response‐adapted consolidation yield an unprecedented depth of response in newly diagnosed multiple myeloma. Patients treated on MASTER (NCT03224507) ceased therapy and entered activ...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Rebecca W. Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Robert F. Cornell, Natalie S. Callander, Luciano J. Costa
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2023-08-01
Serie:	eJHaem
Soggetti:	immunodeficiency measurable residual disease multiple myeloma
Accesso online:	https://doi.org/10.1002/jha2.736
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!